Nucleated red blood cells as a prognostic marker for mortality in patients with SARS-CoV-2-induced ARDS: an observational study.
ARDS
COVID-19
Erythroblasts
ICU
Mortality
NRBC
Prognosis
Prognostic marker
SARS-CoV-2
Journal
Journal of anesthesia, analgesia and critical care
ISSN: 2731-3786
Titre abrégé: J Anesth Analg Crit Care
Pays: England
ID NLM: 9918591885906676
Informations de publication
Date de publication:
28 Jun 2024
28 Jun 2024
Historique:
received:
24
04
2024
accepted:
25
06
2024
medline:
29
6
2024
pubmed:
29
6
2024
entrez:
29
6
2024
Statut:
epublish
Résumé
The presence of nucleated red blood cells (NRBCs) in the peripheral blood of critically ill patients is associated with poor outcome. Evidence regarding the predictive value of NRBCs in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) remains elusive. The aim of this study was to evaluate the predictive validity of NRBCs in these patients. Daily NRBC values of adult patients with SARS-CoV-2-induced ARDS were assessed and their predictive validity for mortality was statistically evaluated. A cut-off level based on the patient's maximum NRBC value during ICU stay was calculated and further specified according to Youden's method. Based on this cut-off value, further analyses such as logistic regression models and survival were performed. 413 critically ill patients with SARS-CoV-2-induced ARDS were analyzed. Patients who did not survive had significantly higher NRBC values during their ICU stay compared to patients who survived (1090/µl [310; 3883] vs. 140/µl [20; 500]; p < 0.0001). Patients with severe ARDS (n = 374) had significantly higher NRBC values during ICU stay compared to patients with moderate ARDS (n = 38) (490/µl [120; 1890] vs. 30/µl [10; 476]; p < 0.0001). A cut-off level of NRBC ≥ 500/µl was found to best stratify risk and was associated with a longer duration of ICU stay (12 [8; 18] vs. 18 [13; 27] days; p < 0.0001) and longer duration of mechanical ventilation (10 [6; 16] vs. 17 [12; 26] days; p < 0.0001). Logistic regression analysis with multivariate adjustment showed NRBCs ≥ 500/µl to be an independent risk factor of mortality (odds ratio (OR) 4.72; 95% confidence interval (CI) 2.95-7.62, p < 0.0001). Patients with NRBC values below the threshold of 500/µl had a significant survival advantage over those above the threshold (median survival 32 [95% CI 8.7-43.3] vs. 21 days [95% CI 18.2-23.8], log-rank test, p < 0.05). Patients who once reached the NRBC threshold of ≥ 500/µl during their ICU stay had a significantly increased long-term mortality (median survival 489 days, log-rank test, p = 0.0029, hazard ratio (HR) 3.2, 95% CI 1.2-8.5). NRBCs predict mortality in critically ill patients with SARS-CoV-2-induced ARDS with high prognostic power. Further studies are required to confirm the clinical impact of NRBCs to eventually enhance decision making.
Sections du résumé
BACKGROUND
BACKGROUND
The presence of nucleated red blood cells (NRBCs) in the peripheral blood of critically ill patients is associated with poor outcome. Evidence regarding the predictive value of NRBCs in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) remains elusive. The aim of this study was to evaluate the predictive validity of NRBCs in these patients.
METHODS
METHODS
Daily NRBC values of adult patients with SARS-CoV-2-induced ARDS were assessed and their predictive validity for mortality was statistically evaluated. A cut-off level based on the patient's maximum NRBC value during ICU stay was calculated and further specified according to Youden's method. Based on this cut-off value, further analyses such as logistic regression models and survival were performed.
RESULTS
RESULTS
413 critically ill patients with SARS-CoV-2-induced ARDS were analyzed. Patients who did not survive had significantly higher NRBC values during their ICU stay compared to patients who survived (1090/µl [310; 3883] vs. 140/µl [20; 500]; p < 0.0001). Patients with severe ARDS (n = 374) had significantly higher NRBC values during ICU stay compared to patients with moderate ARDS (n = 38) (490/µl [120; 1890] vs. 30/µl [10; 476]; p < 0.0001). A cut-off level of NRBC ≥ 500/µl was found to best stratify risk and was associated with a longer duration of ICU stay (12 [8; 18] vs. 18 [13; 27] days; p < 0.0001) and longer duration of mechanical ventilation (10 [6; 16] vs. 17 [12; 26] days; p < 0.0001). Logistic regression analysis with multivariate adjustment showed NRBCs ≥ 500/µl to be an independent risk factor of mortality (odds ratio (OR) 4.72; 95% confidence interval (CI) 2.95-7.62, p < 0.0001). Patients with NRBC values below the threshold of 500/µl had a significant survival advantage over those above the threshold (median survival 32 [95% CI 8.7-43.3] vs. 21 days [95% CI 18.2-23.8], log-rank test, p < 0.05). Patients who once reached the NRBC threshold of ≥ 500/µl during their ICU stay had a significantly increased long-term mortality (median survival 489 days, log-rank test, p = 0.0029, hazard ratio (HR) 3.2, 95% CI 1.2-8.5).
CONCLUSIONS
CONCLUSIONS
NRBCs predict mortality in critically ill patients with SARS-CoV-2-induced ARDS with high prognostic power. Further studies are required to confirm the clinical impact of NRBCs to eventually enhance decision making.
Identifiants
pubmed: 38943198
doi: 10.1186/s44158-024-00174-2
pii: 10.1186/s44158-024-00174-2
doi:
Types de publication
Journal Article
Langues
eng
Pagination
38Informations de copyright
© 2024. The Author(s).
Références
Tzotzos SJ, Fischer B, Fischer H, Zeitlinger M. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Crit Care. 2020;24(1). https://doi.org/10.1186/S13054-020-03240-7
Rieg IdS, Von Cube M, Kalbhenn J et al (2020) COVID-19 in-hospital mortality and mode of death in a dynamic and non-restricted tertiary care model in Germany. Published online. https://doi.org/10.1371/journal.pone.0242127
doi: 10.1371/journal.pone.0242127
Schellenberg CM, Lindholz M, Grunow JJ et al (2023) Mobilisation practices during the SARS-CoV-2 pandemic: A retrospective analysis (MobiCOVID). Anaesth Crit Care Pain Med 42(5):101255. https://doi.org/10.1016/J.ACCPM.2023.101255
doi: 10.1016/J.ACCPM.2023.101255
pubmed: 37257753
pmcid: 10226277
Karagiannidis C, Mostert C, Hentschker C et al (2020) Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med 8(9):853–862. https://doi.org/10.1016/S2213-2600(20)30316-7
doi: 10.1016/S2213-2600(20)30316-7
pubmed: 32735842
pmcid: 7386882
Pichler A, Uhlig D (2023) Mortality in Germany during the COVID-19 Pandemic. Int J Environ Res Public Health 20(20):6942. https://doi.org/10.3390/IJERPH20206942
doi: 10.3390/IJERPH20206942
pubmed: 37887680
pmcid: 10606421
Hu B, Guo H, Zhou P, Shi ZL (2021) Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 19(3):141. https://doi.org/10.1038/S41579-020-00459-7
doi: 10.1038/S41579-020-00459-7
pubmed: 33024307
Brandenburg K, Ferrer-Espada R, Martinez-de-Tejada G et al (2023) A Comparison between SARS-CoV-2 and Gram-Negative Bacteria-Induced Hyperinflammation and Sepsis. Int J Mol Sci 24(20):15169. https://doi.org/10.3390/IJMS242015169
doi: 10.3390/IJMS242015169
pubmed: 37894850
pmcid: 10607443
Wolff D, Nee S, Hickey NS, Marschollek M (2021) Risk factors for Covid-19 severity and fatality: a structured literature review. Infection 49(1):15–28. https://doi.org/10.1007/S15010-020-01509-1
doi: 10.1007/S15010-020-01509-1
pubmed: 32860214
Zeng Z, Yu H, Chen H, et al. Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID-19 from Wuhan, China. Crit Care. 2020;24(1). https://doi.org/10.1186/S13054-020-03255-0
Lippi G, Plebani M (2020) Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta 505:190–191. https://doi.org/10.1016/J.CCA.2020.03.004
doi: 10.1016/J.CCA.2020.03.004
pubmed: 32145275
pmcid: 7094472
Danwang C, Endomba FT, Nkeck JR, Wouna DLA, Robert A, Noubiap JJ. A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). Biomark Res. 2020;8(1). https://doi.org/10.1186/S40364-020-00217-0
Li X, Xu S, Yu M et al (2020) Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 146(1):110–118. https://doi.org/10.1016/J.JACI.2020.04.006
doi: 10.1016/J.JACI.2020.04.006
pubmed: 32294485
pmcid: 7152876
De Moura Monteiro Júnior JG, De Oliveira CiprianoTorres D, Da Silva MCFC, et al. Nucleated Red Blood Cells as Predictors of All-Cause Mortality in Cardiac Intensive Care Unit Patients: A Prospective Cohort Study. PLoS One. 2015;10(12). https://doi.org/10.1371/JOURNAL.PONE.0144259
Danise P, MacOni M, Barrella F et al (2011) Evaluation of nucleated red blood cells in the peripheral blood of hematological diseases. Clin Chem Lab Med 50(2):357–360. https://doi.org/10.1515/CCLM.2011.766
doi: 10.1515/CCLM.2011.766
pubmed: 22022981
Desai S, Jones SL, Turner KL, Hall J, Moore LJ (2012) Nucleated red blood cells are associated with a higher mortality rate in patients with surgical sepsis. Surg Infect (Larchmt) 13(6):360–365. https://doi.org/10.1089/SUR.2011.089
doi: 10.1089/SUR.2011.089
pubmed: 23237100
Stachon A, Holland-Letz T, Krieg M (2004) High in-hospital mortality of intensive care patients with nucleated red blood cells in blood. Clin Chem Lab Med 42(8):933–938. https://doi.org/10.1515/CCLM.2004.151
doi: 10.1515/CCLM.2004.151
pubmed: 15387445
Kluge S, Janssens U, Welte T et al (2021) Recommendations for treatment of critically ill patients with COVID-19: Version 3 S1 guideline. Anaesthesist 70(Suppl 1):19–29. https://doi.org/10.1007/S00101-020-00879-3
doi: 10.1007/S00101-020-00879-3
pubmed: 33245382
Vincent JL, Moreno R, Takala J et al (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 22(7):707–710. https://doi.org/10.1007/BF01709751/METRICS
doi: 10.1007/BF01709751/METRICS
pubmed: 8844239
Quan H, Li B, Couris CM et al (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173(6):676–682. https://doi.org/10.1093/AJE/KWQ433
doi: 10.1093/AJE/KWQ433
pubmed: 21330339
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383. https://doi.org/10.1016/0021-9681(87)90171-8
doi: 10.1016/0021-9681(87)90171-8
pubmed: 3558716
Ranieri VM, Rubenfeld GD, Thompson BT et al (2012) Acute respiratory distress syndrome: the Berlin Definition. JAMA 307(23):2526–2533. https://doi.org/10.1001/JAMA.2012.5669
doi: 10.1001/JAMA.2012.5669
pubmed: 22797452
Fluss R, Faraggi D, Reiser B (2005) Estimation of the Youden Index and its associated cutoff point. Biom J 47(4):458–472. https://doi.org/10.1002/BIMJ.200410135
doi: 10.1002/BIMJ.200410135
pubmed: 16161804
Noor T, Imran A, Raza H, Sarwar M, Umer S, Fatima M. Frequency of Nucleated Red Blood Cells in the Peripheral Blood of ICU-Admitted Patients. Cureus. 2023;15(1). https://doi.org/10.7759/CUREUS.33827
Menk M, Giebelhäuser L, Vorderwülbecke G et al (2018) Nucleated red blood cells as predictors of mortality in patients with acute respiratory distress syndrome (ARDS): an observational study. Ann Intensive Care 8:42. https://doi.org/10.1186/s13613-018-0387-5
doi: 10.1186/s13613-018-0387-5
pubmed: 29589209
pmcid: 5869325
Schmidt G, Martens A, Koch C et al (2024) Nucleated red blood cells are a late biomarker in predicting intensive care unit mortality in patients with COVID-19 acute respiratory distress syndrome: an observational cohort study. Front Immunol 15:1313977. https://doi.org/10.3389/FIMMU.2024.1313977
doi: 10.3389/FIMMU.2024.1313977
pubmed: 38304431
pmcid: 10830722
Gabr H, Bastawy S, Abdel Aal A, Khalil NM, Fateen M (2022) Changes in peripheral blood cellular morphology as diagnostic markers for COVID-19 infection. Int J Lab Hematol 44(3):454–460. https://doi.org/10.1111/ijlh.13799
doi: 10.1111/ijlh.13799
pubmed: 35048518
Smadja DM, Mentzer SJ, Fontenay M et al (2021) COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects. Angiogenesis 24(4):755. https://doi.org/10.1007/S10456-021-09805-6
doi: 10.1007/S10456-021-09805-6
pubmed: 34184164
pmcid: 8238037
Pikora K, Krętowska-Grunwald A, Krawczuk-Rybak M, Sawicka-Żukowska M. Diagnostic Value and Prognostic Significance of Nucleated Red Blood Cells (NRBCs) in Selected Medical Conditions. Cells. 2023;12(14). https://doi.org/10.3390/CELLS12141817
Zimmerman GA, Albertine KH, Carveth HJ et al (1999) Endothelial Activation in ARDS*. Chest. 116(1 Suppl):18S–24S
doi: 10.1378/chest.116.suppl_1.18S
pubmed: 10424566
Purtle SW, Horkan CM, Moromizato T, Gibbons FK, Christopher KB. Nucleated red blood cells, critical illness survivors and postdischarge outcomes: a cohort study. Crit Care. 2017;21(1). https://doi.org/10.1186/S13054-017-1724-Z